Atlas Trials

Neoadjuvant and Adjuvant Tislelizumab for Nasopharyngeal Carcinoma

Clinical trial NCT05448885 · UNKNOWN

Trial details

NCT number
NCT05448885
Sponsor
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Status
UNKNOWN
Phase
Phase 2
Study type
INTERVENTIONAL
Nasopharyngeal Carcinoma
Start date
2021-09-01
Primary completion
2025-09-01
Enrollment
50

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.